Search

Your search keyword '"Falge, Christiane"' showing total 152 results

Search Constraints

Start Over You searched for: Author "Falge, Christiane" Remove constraint Author: "Falge, Christiane"
152 results on '"Falge, Christiane"'

Search Results

6. Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

8. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML

12. Orientierungshilfen zum Umgang mit Gesundheitsinformationen im Internet: Diversitätssensible Stärkung digitaler Gesundheitskompetenz

13. Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia

14. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV

15. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV

22. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

23. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

25. Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA

26. Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA

28. Defining Therapy Goals for Major Molecular Remission in Chronic Myeloid Leukemia: Results of the Randomized CML-Study IV

29. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: Update on the Survival Outcome Following Allogeneic HSCT after Imatinib Failure; Results of the German CML Study IV

30. A Two-Fold Rise of BCR-ABL Transcript Levels Advises BCR-ABL Mutation Analysis in Imatinib-Treated Chronic Myeloid Leukemia (CML) - an Analysis of the Randomized CML-Study IV

31. Comparing the Prognostic Significance of Early Predictors of Survival in Chronic Myeloid Leukemia (CML) Treated with Imatinib - an Analysis of the Randomized CML-Study IV

33. Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

34. Prognostic Factors Identified Via a Cox Proportional Hazard Cure Model Explain Survival Differences After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myeloid Leukemia (CML) Between Two Consecutive Patient Cohorts

35. Comorbidity, Measured By The Charlson Index, Has No Negative Impact On Remission In Patients With Chronic Myeloid Leukemia: Results Of The Randomized CML-Study IV

36. Adverse Events (AE) Under Imatinib Treatment Over 10 Years: Results From 1501 Patients Of The Randomized CML-Study IV

37. The Cytogenetic Profile In Lymphoid and Myeloid CML Blast Crisis

38. Achievement Of a MR5.0 Within the Randomized CML-Study IV: Feasibility, Differences Between Treatment Arms, and Prognostic Implications

39. Optimizing Early Prediction Of Outcome In CML Using The Exact Decline Of BCR-ABL Transcript Levels Within 3 Months Of Imatinib Treatment As a Prognostic Marker

40. The Impact Of Balanced and Unbalanced Karyotypes On Prognosis Of CML: From Chronic Phase To Blast Crisis

41. Absolute BCR-ABL Transcript Levels At 3 Months but Not At Diagnosis Predict Survival of Chronic Myeloid Leukemia (CML) Patients On Imatinib Therapy

42. Secondary Malignancies in CML Patients – Data From the German CML Study IV

43. Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV

44. Impact of Balanced or Unbalanced Karyotype At Diagnosis On Prognosis of CML: Long-Term Observation From 1346 Patients of the Randomized CML Study IV

45. Impact of Additional Cytogenetic Alterations At Diagnosis on Prognosis of CML: Long-Term Observation From 1151 Patients of the Randomized CML Study IV

46. Therapy with Imatinib In Elderly CML Patients (>65years): Results of the German CML-Study IV.

47. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

48. Distinct Characteristics of e13a2 versus e14a2 BCR-ABL Chronic Myeloid Leukemia under Upfront Treatment with Imatinib – an Analysis of the German CML Study IV,

49. Prediction of Molecular Response of Chronic Phase CML Patients by the EUTOS Score: Results of the Randomized CML-Study IV,

50. Time-Related Interpretation of Molecular Response Levels According to Long Term Overall and Progression-Free Survival of CML Patients on First-Line Imatinib Treatment

Catalog

Books, media, physical & digital resources